# Mobia Medical, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Mobia Medical, Inc.). ## Overview Mobia Medical, Inc. is a U.S.-based medical device company focused on stroke recovery. Its core product is the Vivistim Paired Vagus Nerve Stimulation System, which is used to support therapy for chronic ischemic stroke survivors with upper-extremity motor impairment. ## Products & services • Vivistim Paired Vagus Nerve Stimulation System • Implantable stroke recovery therapy system • Accessories and replenishment product • Commercial support for stroke centers • Clinical and regulatory development activities - **Vivistim System** (90%) — Implantable neurostimulation system used in stroke rehabilitation therapy. - **Accessories and replenishment products** (10%) — Consumable and replacement items sold alongside the installed base. - Vivistim Paired Vagus Nerve Stimulation System - Implantable stroke recovery therapy system - Accessories and replenishment product - Commercial support for stroke centers - Clinical and regulatory development activities ## Customers The company sells primarily to primary and comprehensive stroke centers in the United States, where the Vivistim System is implanted and used in patient care. These hospitals typically buy an initial stocking order and then reorder replenishment product as procedures are performed. Adoption also depends on physicians, therapy sites, and payer coverage because the therapy is tied to post-stroke rehabilitation pathways. - **Primary stroke centers** (primary) — Hospitals that perform most Vivistim implants and buy the system for stroke recovery programs. - **Comprehensive stroke centers** (primary) — Higher-acuity stroke hospitals that adopt the system for eligible chronic stroke patients. - **Group purchasing organizations and IDNs** (secondary) — Buying groups that negotiate pricing and contract access for affiliated hospitals and ASCs. - **Therapy and neurorehabilitation sites** (secondary) — Facilities that support post-implant rehabilitation and help drive therapy utilization. - **Payors and coverage decision-makers** (secondary) — Private and governmental payors that influence adoption through reimbursement coverage. - Primary stroke centers that implant Vivistim systems - Comprehensive stroke centers that treat complex stroke cases - Hospitals and ASCs buying through GPO/IDN contracts - Therapy sites with neurorehabilitation capabilities - Patients with chronic ischemic stroke-related motor impairment ## Geography Mobia Medical generates substantially all of its revenue in the United States, where it sells the Vivistim System to stroke centers. Its commercial footprint is built around concentrated high-volume stroke hospitals and the surrounding rehabilitation network, so U.S. reimbursement and hospital contracting are central to the business. The company also relies on third-party manufacturers and suppliers, which adds operational exposure even though end-market sales are domestic. - Substantially all revenue comes from the United States - Commercial focus is on U.S. primary and comprehensive stroke centers - Therapy adoption depends on nearby neurorehabilitation networks - GPO and IDN contracting shapes access across U.S. hospitals - Third-party manufacturing and suppliers support the U.S. business ## Strategy The company is focused on expanding commercial reach, adding stroke centers, and increasing awareness of Vivistim Therapy among clinicians and patients. It also seeks broader payer coverage and continued clinical and regulatory work to support adoption of the therapy. Because the business is concentrated in a specialized hospital channel, execution depends on scaling the sales organization efficiently and maintaining supply continuity. - **Expand commercial coverage in stroke centers** (short-term) — The product is sold into a concentrated hospital channel, so more field coverage can increase implants and reorders. - **Improve payer coverage and reimbursement** (medium-term) — Coverage policies directly affect hospital willingness to adopt and patients' access to therapy. - **Support clinical evidence and regulatory work** (medium-term) — Clinical validation and regulatory compliance reinforce adoption in a specialized medical device market. - **Scale supply chain and manufacturing capacity** (medium-term) — Third-party manufacturing must keep pace with demand and quality requirements. - Expand the commercial organization and sales territories - Increase awareness and utilization of Vivistim Therapy - Broaden payer coverage to support adoption and reimbursement - Continue clinical studies and regulatory activities - Scale manufacturing and supplier capacity through third parties ## Risks Mobia Medical faces commercialization risk because adoption depends on hospital contracting, reimbursement, and clinician awareness in a narrow stroke-care market. It also relies on third-party manufacturers and suppliers, which creates quality, supply, and continuity risk if components or finished goods are delayed or unavailable. As a medical device company, it is also exposed to competitive pressure, technological change, and ongoing losses while it scales. - **GPO and IDN contracting pressure** [high] — Buying groups negotiate category-by-category and can force lower prices or fewer vendors. - **Reimbursement and coverage risk** [high] — Adoption depends on payer policies for procedures using Vivistim. - **Third-party manufacturing and supplier dependence** [high] — Single-source or limited suppliers can delay shipments, raise costs, or cause recalls. - **Competitive and technology risk** [medium] — Larger medical device and robotics companies have greater scale, resources, and relationships. - **Ongoing losses and capital needs** [high] — Commercial expansion, clinical work, and public-company costs can require additional funding. - Hospital GPO and IDN pricing pressure can reduce margins and access - Reimbursement and coverage uncertainty can slow adoption - Third-party manufacturing creates supply and quality risk - Competition from larger device and robotics companies is intense - The company has a history of losses and may need continued capital ## Accounting The most important accounting judgments are stock compensation and valuation of common stock, which can materially affect reported expenses and equity values. Revenue is concentrated in product sales of the Vivistim System, so investors should watch shipment timing, stocking orders, and replenishment patterns that can create quarter-to-quarter volatility. Lease accounting, purchase commitments, and fair-value changes on convertible notes and warrant liabilities also affect reported results and balance-sheet presentation. - **Stock compensation and common stock valuation** — Reported operating expenses and equity valuation - **Revenue timing for Vivistim system sales** — Quarterly revenue comparability - **Operating leases** — Balance sheet and operating expense recognition - **Convertible notes and warrant liabilities** — Net income volatility - **Purchase commitments and supplier obligations** — Cash flow and working capital - Stock compensation and common stock valuation are key estimates - Product shipment timing can create quarterly revenue volatility - Lease liabilities affect operating lease expense and obligations - Purchase commitments reflect supply-chain and inventory planning - Fair value changes on convertible notes and warrants affect other income --- *Last updated: 2026-06-16T23:02:23.223616+00:00*